Turbine, a leading developer of cell simulations with AI, today announced a research collaboration with MSD (the tradename of ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has ...

A mum who enrolled in a college course after her son’s type 1 diabetes diagnosis is now building a successful career in science after 20 years ...

U.S. FDA Accepts New Drug Application for Merck’s DOR/ISL Once-Daily Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1.

Employees of the technology transfer centre ANAXAM and researchers from the Paul Scherrer Institute PSI used the unique ...

Strengthens 90-year legacy of partnership between MilliporeSigma and WashU to accelerate scientific progress Strategic academic-industry alliance aims to build robust Research & Development talent ...

Rahway, New Jersey Saturday, July 12, 2025, 09:00 Hrs [IST] ...

Poster presentation of updated data on BT-001 from the Phase 1 part of the ongoing Phase 1/2a study in solid tumors - LUND, SE / ACCESS Newswire / July 28, 2025 / BioInvent International AB ("BioInven ...

Employees of the technology transfer centre ANAXAM and researchers from the Paul Scherrer Institute PSI used the unique ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep” or 'the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for ...

The abstract will be available on ESMO’s website on October 13, 2025, at 00:05 CEST.